Bryant Carruth, MD
Ophthalmic Plastic and Reconstructive Surgery · North Syracuse, NYNPI 1760645790
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,780 of the $37,935 with a category attached, or 83.8%. Amgen accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $15,434 and has fallen 98.2% since, to $283 in 2025.
Across 65 payments — averaging $583.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$38K
- Biotissue Holdings Inc.$16
- AbbVie$15
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$31,78084%
- Travel & lodging$4,69912%
- Food & beverage$1,4114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 63 | $37,904 |
| Biotissue Holdings Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$36,325
How this compares
$37,935 in reported general payments places this provider in the 75th percentile of 25 ophthalmic plastic and reconstructive surgery providers in New York.
See all ophthalmic plastic and reconstructive surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 669 | $6,683 |
| Fluorometholone | 41 | $2,785 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 101 | $1,000 |
| Doxycycline Hyclate | 33 | $632 |
| Prednisolone Acetate | 17 | $552 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in North Syracuse
- George SalloumNorth Syracuse$141K
- Thomas BersaniNorth Syracuse$1K
- Gary Lelli JrNew York$263K
- James ChelnisNew York$223K
- Edward WladisSlingerlands$179K
- Joseph ArmeniaWebster$38K
- Kira SegalNew York$12K
- Leon RafailovSmithtown$5K
- Daniel KhodadadianGreat Neck$4K
- Katherine WhippleRochester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.